349-49-5

Usage

Uses

Used in Pharmaceutical Industry:
4-TRIFLUOROMETHYL-THIAZOL-2-YLAMINE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in HIV Treatment:
4-TRIFLUOROMETHYL-THIAZOL-2-YLAMINE is used as a starting material for the preparation of phenethylthiazolylthiourea analogs, which have been identified as HIV-1 reverse transcriptase inhibitors. These inhibitors play a crucial role in the development of antiretroviral drugs, helping to combat the HIV virus by blocking the replication process.
Used in Diabetes Management:
4-TRIFLUOROMETHYL-THIAZOL-2-YLAMINE can also be used to synthesize 2-amino benzamide derivatives, which act as allosteric glucokinase activators. These activators are important in the regulation of glucose metabolism and have potential applications in the treatment of type 2 diabetes. By enhancing the activity of glucokinase, these derivatives can help improve insulin secretion and glucose homeostasis, contributing to better diabetes management.

InChI:InChI=1/C4H3F3N2S/c5-4(6,7)2-1-10-3(8)9-2/h1H,(H2,8,9)

Upstream product

• 431-37-8 3-chloro-1,1,1-trifluoroacetone 
• 17356-08-0 thiourea 
• 431-35-6 3-bromo-1,1,1-trifluoroacetone 
• 533887-24-0 2-(phenylsulfonyl)-3-(trifluoromethyl)oxirane 
• 433-26-1 1,1,1-trifluoro-3-diazo-2-oxopropane 
• 1349091-16-2 C₉H₇F₃OS 
• 169260-95-1 2-Trifluoromethyl-2-phenylsulfonyloxirane 

Downstream Products

• 136411-21-7 2-amino-5-bromo-4-(trifluoromethyl)thiazole 
• 959746-45-3 2-ethoxy-N-(4-trifluoromethyl-thiazol-2-yl)-benzamide 
• 682342-65-0 2-amino-5-iodo-4-trifuloromethylthiazole 
• 41731-39-9 2-bromo-4-(trifluoromethyl)thiazole 
• 864376-14-7 2-iodo-4-trifluoromethyl-thiazole 
• 1208552-81-1 C₁₅H₁₄ClF₃N₂OS 
• 1219122-55-0 3,4-dinitro-N-(4-trifluoromethyl-thiazol-2-yl)-benzamide 
• 1228828-89-4 6-{(E)-2-[3-Difluoromethoxy-2-(2,2-dimethylpropoxy)phenyl]vinyl}-N-[4-(trifluoro-methyl)-1,3-thiazol-2-yl]imidazo[2,1-b][1,3]thiazole-5-carboxamide 
• 1236429-58-5 3-(trifluoromethyl)-N-(4-(trifluoromethyl)thiazol-2-yl)benzamide 
• 1236429-55-2 N-(4-(trifluoromethyl)thiazol-2-yl)benzamide 
• 1254956-24-5 2-acetoxybenzoyl-N-(4-trifluoromethyl)thiazol-2-yl amide 
• 64932-39-4 N-(4-trifluoromethyl-thiazol-2-yl)-acetamide 
• 1063724-92-4 4-{[(4-(trifluoromethyl)-1,3-thiazol-2-yl)amino]sulfonyl}-N-[4-(trifluoromethyl)benzyl]benzamide 
• 228119-52-6 2-Chloro-4-(trifluoromethyl) thiazole 

Relevant academic research and scientific papers

A novel access to 4-trifluoromethyl-1,3-thiazole derivatives via an intermediate thiocarbonyl ylide

A Lewis acid catalyzed reaction of trifluoroacetyldiazomethane (CF3COCHN2) with thiourea occurs in boiling THF solution in the presence of BF3·OEt2 yielding 2-amino-4-trifluoromethyl-1,3-thiazole in a fair yield

NOVEL COMPOUNDS WITH A 3A-AZABICYCLO [4.1.0] HEPTANE CORE ACTING ON OREXIN RECEPTORS

This invention relates to azabicyclo[4.1.0]hept-4-yl derivatives and their use as pharmaceuticals.

Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis c virus replication

We report the activities of a number of thiazolides [2-hydroxyaroyl-N- (thiazol-2-yl)amides] against hepatitis C virus (HCV) genotypes IA and IB, using replicon assays. The structure-activity relationships (SARs) of thiazolides against HCV are less predic

CARBACEPHEM BETA-LACTAM ANTIBIOTICS

Carbacephem β-lactam antibiotics having chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R6 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

CARBACEPHEM β-LACTAM ANTIBIOTICS

Carbacephem -lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar1, Ar2, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS

The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are pro

THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological dise

ARYL SULFONES AND USES RELATED THERETO

Aryl sulfone compounds of formula (I) and (II) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed